LigronBio is a biotechnology company advancing novel molecular glue therapeutics to enable targeted protein degradation and drug the undruggable. The company integrates computational chemistry, machine learning, and AI with experimental data—anchored by its TriMatrix Analyzer platform—to accelerate discovery and candidate design. LigronBio expands the E3 ligase toolkit and partners from early research through clinical development to translate these innovations across oncology, neurology, and other disease areas.
Subscribe to our newsletter to stay up to date with the latest news.
